Novo Nordisk is rated a strong buy, offering a 4.2% yield and trading at a 40% discount to fair value. Click here to read ...
There is light at the end of the tunnel.
7hon MSN
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with ...
At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Novo Nordisk CEO Mike ...
Novo Nordisk (CPSE:NOVO B) reported positive phase 2 data for its investigational drug amycretin (zenagamtide), a dual GLP-1 and amylin receptor agonist. The phase 2 trial in adults with type 2 ...
Ltd. (“Novo Nordisk”) reaffirms its unwavering commitment to patient safety and medicine quality following recent reports of ...
Novo Nordisk (NYSE: NVO), previously the early mover in the GLP-1 weight loss drug space, has lost its edge as competitor Eli ...
Novo Nordisk's oral Wegovy pill has exceeded 3 million prescriptions in the U.S. within five months, expanding the obesity ...
Novo Nordisk ( NVO 1.85%), previously the early mover in the GLP-1 weight loss drug space, has lost its edge as competitor ...
A mom in America who couldn't afford GLP-1 injections has started the new "cheaper" Wegovy pill that's currently awaiting ...
Novo Nordisk today announced the launch of Wegovy® pill (semaglutide tablets) in the United Arab Emirates (UAE), the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results